Research Analysts Offer Predictions for Genelux Q1 Earnings

Genelux Co. (NASDAQ:GNLX) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Genelux in a research note issued on Tuesday, March 25th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings per share of ($0.16) for the quarter. HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Genelux’s Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.22) EPS and FY2029 earnings at $2.58 EPS.

Genelux Stock Performance

Shares of GNLX stock opened at $3.40 on Wednesday. Genelux has a fifty-two week low of $1.60 and a fifty-two week high of $6.50. The stock’s fifty day moving average is $4.02 and its two-hundred day moving average is $3.09. The firm has a market capitalization of $117.43 million, a P/E ratio of -3.58 and a beta of -1.41.

Hedge Funds Weigh In On Genelux

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Virtu Financial LLC purchased a new position in Genelux in the 4th quarter worth approximately $25,000. Apollon Wealth Management LLC boosted its stake in Genelux by 20.4% during the fourth quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock worth $40,000 after buying an additional 2,857 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Genelux in the 4th quarter valued at $41,000. Brown Brothers Harriman & Co. raised its holdings in shares of Genelux by 76.2% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 21,075 shares of the company’s stock worth $50,000 after acquiring an additional 9,114 shares during the period. Finally, D.A. Davidson & CO. acquired a new position in shares of Genelux during the 4th quarter valued at about $51,000. 37.33% of the stock is currently owned by institutional investors and hedge funds.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.